A Phase IV, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically ill Patients
Latest Information Update: 14 Dec 2022
At a glance
- Drugs Posaconazole (Primary)
- Indications Invasive bronchopulmonary aspergillosis
- Focus Proof of concept; Therapeutic Use
- Acronyms POSA-FLU
- 29 Jun 2022 Status changed from discontinued to completed.
- 01 Jun 2022 Results of pharmacokinetics analysis of observational sub-study of this study was published in the Mycoses.
- 23 Jul 2021 Cannot access eudract record, kindly update later